SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Lupin’s Goa facility

20 Sep 2021 Evaluate

The United States Food and Drug Administration (USFDA) has concluded an inspection at Lupin’s Goa facility in India. The inspection was carried out from September 6, 2021 to September 18, 2021 and closed with seven observations.

The company is confident of addressing the observations satisfactorily and is committed to be compliant with Good Manufacturing Practice standards across all its facilities.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2240.70 -4.95 (-0.22%)
12-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.90
Dr. Reddys Lab 1270.10
Cipla 1295.15
Zydus Lifesciences 932.00
Lupin 2240.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×